"Receptor, ErbB-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF RECEPTOR and the ERBB-2 RECEPTOR. Overexpression of the erbB-3 receptor is associated with TUMORIGENESIS.
| Descriptor ID |
D020893
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.500 D12.776.543.750.630.009.500 D12.776.543.750.750.400.074.500 D12.776.624.664.700.790 D23.101.140.721
|
| Concept/Terms |
Receptor, ErbB-3- Receptor, ErbB-3
- ErbB-3 Receptor
- Receptor, ErbB 3
- Proto-Oncogene Protein erbB-3
- Proto Oncogene Protein erbB 3
- erbB-3, Proto-Oncogene Protein
- erbB-3 Protein
- erbB 3 Protein
- HER-3 Proto-Oncogene Protein
- HER 3 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-3
- Tyrosine Kinase-type Cell Surface Receptor HER3
- Tyrosine Kinase type Cell Surface Receptor HER3
- Proto-Oncogene Proteins erbB-3
- Proto Oncogene Proteins erbB 3
- erbB-3, Proto-Oncogene Proteins
- Proto-oncogene-like Protein c-ErbB-2
- Protein c-ErbB-2, Proto-oncogene-like
- Proto oncogene like Protein c ErbB 2
- c-ErbB-2, Proto-oncogene-like Protein
- c-erbB-3 Protein
- c erbB 3 Protein
- Proto-Oncogene Protein c-erbB-3
- Proto Oncogene Protein c erbB 3
- c-erbB-3, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-3 [D08.811.913.696.620.682.725.400.009.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-3 [D12.776.543.750.630.009.500]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-3 [D12.776.543.750.750.400.074.500]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-3 [D12.776.624.664.700.790]
- Biological Factors [D23]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-3 [D23.101.140.721]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-3".
This graph shows the total number of publications written about "Receptor, ErbB-3" by people in this website by year, and whether "Receptor, ErbB-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-3" by people in Profiles.
-
Black LE, Longo JF, Carroll SL. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Am J Pathol. 2019 10; 189(10):1898-1912.
-
Bandyopadhyay A, Favours E, Phelps DA, Pozo VD, Ghilu S, Kurmashev D, Michalek J, Trevino A, Guttridge D, London C, Hirotani K, Zhang L, Kurmasheva RT, Houghton PJ. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer. 2018 Feb; 65(2).
-
Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010 Oct 15; 70(20):7862-73.
-
Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control. 2010 Mar; 21(3):399-409.
-
Shilabin AG, Kasanah N, Wedge DE, Hamann MT. Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem. 2007 Sep 06; 50(18):4340-50.
-
Ritch PS, Carroll SL, Sontheimer H. Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia. 2005 Aug 15; 51(3):217-28.
-
Pearson RJ, Carroll SL. ErbB transmembrane tyrosine kinase receptors are expressed by sensory and motor neurons projecting into sciatic nerve. J Histochem Cytochem. 2004 Oct; 52(10):1299-311.
-
Fallon KB, Havlioglu N, Hamilton LH, Cheng TP, Carroll SL. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neurooncol. 2004 Feb; 66(3):273-84.
-
Frohnert PW, Stonecypher MS, Carroll SL. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Glia. 2003 Aug; 43(2):104-18.
-
Ritch PA, Carroll SL, Sontheimer H. Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. J Biol Chem. 2003 Jun 06; 278(23):20971-8.